Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company whose news flow centers on glaucoma, corneal disorders, and retinal diseases. The company’s updates frequently highlight its Micro-Invasive Glaucoma Surgery (MIGS) platform, long-duration intracameral implants, and bio-activated pharmaceutical therapies for chronic eye conditions.
Investors following GKOS news can expect regular announcements on financial performance, including quarterly and annual net sales results, segment trends in glaucoma and corneal health, and updates to revenue guidance ranges. These disclosures are often accompanied by conference call and webcast details, as well as supplemental materials such as quarterly summary documents.
Product and pipeline developments are another major focus of Glaukos news. Recent communications have described the commercial launch activities for iDose TR, a long-duration intracameral procedural pharmaceutical implant for glaucoma, and U.S. FDA approval of Epioxa HD / Epioxa, an incision-free, epithelium-on corneal collagen cross-linking therapy for keratoconus. The company also highlights scientific presentations and posters featuring its technologies at major ophthalmology meetings.
Corporate and operational updates appear in the news flow as well, including participation in healthcare and investor conferences and plans for a new research, development, and manufacturing facility in Huntsville, Alabama. Together, these items provide insight into Glaukos’ commercial execution, research pipeline, manufacturing expansion, and overall strategy in ophthalmic pharmaceuticals and medical technology.
For market participants, the GKOS news page offers a consolidated view of these developments, making it easier to track key milestones in glaucoma devices, corneal cross-linking therapies, and other chronic eye disease initiatives reported by the company.
Glaukos (NYSE: GKOS) published its 2025 Sustainability Report highlighting progress on corporate sustainability, patient access, governance, and operations.
Key metrics: $22 million in product donations to date, ~870 volunteer hours, outreach to ~15,000 patients, ~14,000 keratoconus patients served, FDA approval for Epioxa, groundbroken for a new Huntsville R&D and manufacturing facility, 100% cybersecurity training completion, and external limited assurance of GHG disclosures.
Glaukos (NYSE: GKOS) received a permanent HCPCS J-code J2789 for Epioxa, effective July 1, 2026. The company says the product-specific code should streamline reporting, billing, and payment by U.S. payers over time, supporting market access and the planned commercial launch for keratoconus treatment.
Epioxa is described as an incision-free, oxygen-enriched topical therapy bioactivated by UV light that avoids epithelial removal and aims to reduce pain and recovery versus traditional cross-linking.
Glaukos (NYSE: GKOS) will release first quarter 2026 financial results after the market close on April 29, 2026. Management will host a conference call and simultaneous webcast on April 29 at 1:30 p.m. PT / 4:30 p.m. ET.
Live webcast access is available at http://investors.glaukos.com. U.S. dial-in is 800-715-9871, international 646-307-1963, Conference ID 1333241. A replay will be archived on the company website after the call.
Glaukos (NYSE:GKOS) will present multiple scientific abstracts and exhibit at the ASCRS Annual Meeting, April 10–13, 2026, in Washington, D.C. The company will staff booth #407 and sponsor an educational symposium introducing Epioxa on April 10, 2026, from 12:00–1:00 p.m. ET.
Presentations cover glaucoma and corneal health, including outcomes for trabecular micro-bypass stents and travoprost intracameral implants, plus posters on corneal cross-linking and device safety.
Glaukos (NYSE: GKOS) announced commercial availability of Epioxa on March 19, 2026, the first FDA‑approved, incision‑free topical drug therapy for keratoconus.
Epioxa is an oxygen‑ and light‑catalyzed topical corneal cross‑linking treatment intended to reduce pain and recovery time versus epithelium‑removing procedures. Orders are available directly from Glaukos and via specialty distributors. The company said it will expand patient awareness, access programs, and financial assistance to address underdiagnosis and undertreatment.
Glaukos (NYSE:GKOS) reported record Q4 2025 net sales of $143.1M (+36% YoY) and full-year 2025 net sales of $507.4M (+32% YoY). The company recorded a one-time $112.9M impairment tied to an acquired intangible asset, driving a GAAP net loss of $187.7M for 2025. Glaukos ended Q4 with $282.6M in cash and no debt, and reaffirmed 2026 net sales guidance of $600M–$620M.
Non-GAAP gross margin remained strong at ~84%, while non-GAAP operating and net losses narrowed versus 2024.
Glaukos (NYSE:GKOS) announced U.S. FDA approval of an NDA labeling supplement dated January 28, 2026 permitting re-administration of iDose TR under a repeat treatment protocol.
The approval follows Glaukos' 2025 supplement and is supported by clinical evidence showing no clinically significant corneal endothelial cell loss through three years and a safe, well-tolerated second administration over 12 months.
Glaukos (NYSE: GKOS) will release its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Management will discuss results in a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A live webcast link will be available at the company's investor website.
To join the call dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the investor website after the call.
Glaukos (NYSE: GKOS) reported preliminary, unaudited net sales of approximately $143 million for Q4 2025 (up 36% year-over-year) and approximately $507 million for full year 2025 (up 32% year-over-year). Q4 sales mix: U.S. Glaucoma $86M (iDose TR $45M), International Glaucoma $33M, Corneal Health $24M. Full year mix: U.S. Glaucoma $299M (iDose TR $136M), International Glaucoma $122M, Corneal Health $86M. The company ended Q4 with approximately $283M in cash, cash equivalents and short-term investments and no debt. Glaukos reaffirmed 2026 net sales guidance of $600M–$620M. Preliminary results are subject to revision when final results are released after market close on Feb 17, 2026, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Glaukos (NYSE:GKOS) said its management will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 4:30 p.m. PT in San Francisco.
A live and archived webcast will be available in the Investors section of the company website for viewers who cannot attend in person.